By Robert King
State officials are asking for more time and predictability when the COVID-19 public health emergency ends and when Medicaid eligibility redeterminations are expected to start.
read more
By Kyle LaHucik
Sparking innovation at a Big Pharma with a 150-year history can be difficult, so sometimes it takes some outside perspective to get the ball rolling. That's where Leaps by Bayer comes in.
read more
By Conor Hale
Working with the Mayo Clinic to improve its accuracy, the updated version could result in fewer unnecessary recommendations for follow-up colonoscopies, the company said.
read more
By Eric Sagonowsky
After a high-profile study turned up safety risks for Pfizer's JAK inhibitor Xeljanz last year, the FDA put the entire class under a microscope—and it only recently went back to granting new approvals in that class. Bristol Myers Squibb, meanwhile, has a new candidate that the company's chief medical officer says is safer than the other JAKs.
read more
By Heather Landi
Drug development is expensive, can take years to complete and doesn't guarantee a novel therapy for treating disease. But consumer genetic testing company 23andMe is forging ahead to leverage its massive database of genetic data for research and to make and sell its own therapies.
read more
By Annalee Armstrong
Alnylam executives are heralding the replication of data between approved medicine Onpattro and the investigational treatment vutrisiran, which the company is trying to position as an easier-to-administer, next-generation treatment for transthyretin-mediated amyloidosis. Analysts, however, noted a few subtle differences where vutrisiran differed from the approved medicine.
read more
By Conor Hale
Sensor maker Rockley Photonics reported that a pilot study of its wrist-worn device was able to measure a person’s blood pressure without the squeeze of a cuff.
read more
By Ben Adams
As a British citizen living in England but writing on American drug names, I’m in the perfect position to know that many drugs approved in Europe and the U.K. can have very different names from those in the U.S.
read more
By Rebecca Torrence
CVS Health is teaming up with Uber Health, the ride-sharing giant's healthcare arm, to offer free rides to medical care, work and education in high-risk communities.
read more
By Kyle LaHucik
Mirati Therapeutics' KRAS drug adagrasib led to a 41% response rate in patients with pancreatic and other gastrointestinal tumors, the latest in the biotech's efforts to eke out an edge against the big winner in the drug class, Amgen.
read more
By Conor Hale
A new high-speed cell sorting technology could help do more than find the proverbial needle in the haystack, but also categorize each individual strand of hay itself.
read more
